Targeted gene therapies, such as LIM domain only 7 (LMO7) modulation and N6-methyladenosine (m6A) RNA modifications, have been identified as potential regulators of the immune response and tumour progression [9,10]. The gene discussed is LMO7; the disease is neoplasm.